PPAR-α agonists are still on the rise: an update on clinical and experimental findings

References

• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Dallinga-Thie GM, Kroon J, Boren J, et al. Triglyceride-rich lipoproteins and remnants: targets for therapy? Curr Cardiol Rep. 2016;18(7):67.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;2016(253):281–344.
   Google Scholar
• Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb Vasc Biol. 1992;12(1):6–18.
   Google Scholar
• Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15(4):534–542.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–635.
   PubMed Web of Science ®Google Scholar
• Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834–1842.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–458.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7(5):325–331.
   PubMedGoogle Scholar
• Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008;4(1):131–141.
   PubMedGoogle Scholar
• Mansour M. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog Mol Biol Transl Sci. 2014;121:217–266.
   PubMed Web of Science ®Google Scholar
• Liu ZM, Hu M, Chan P, et al. Early investigational drugs targeting PPAR-alpha for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015;24(5):611–621.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314–345.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol. 2014;8(5):473–488.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–1245.
   PubMed Web of Science ®Google Scholar
• Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103(23):2828–2833.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Bezafibrate Infarction Prevention s. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–27.
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154(5):943–953.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692–694. author reply 94-5
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217(2):492–498.
   PubMed Web of Science ®Google Scholar
• Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr Cardiol Rep. 2012;14(1):112–124.
   PubMed Web of Science ®Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2016 Dec 28. doi: 10.1001/jamacardio.2016.4828. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106(6):757–763.
   PubMed Web of Science ®Google Scholar
• Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518–533.
   PubMed Web of Science ®Google Scholar
• Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Recept Channels. 2001;7(4):249–258.
   PubMedGoogle Scholar
• Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta. 2007;1771(8):915–925.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28(1):39–46.
   PubMed Web of Science ®Google Scholar
• Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 2007;3(1):33–39.
   PubMedGoogle Scholar
• Sirtori CR, Galli C, Franceschini G. Fraudulent (and non fraudulent) fatty acids for human health. Eur J Clin Invest. 1993;23(11):686–689.
   PubMed Web of Science ®Google Scholar
• Backes J, Anzalone D, Hilleman D, et al. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016;15(1):118.
   PubMed Web of Science ®Google Scholar
• EPANOVA® safely and effectively. Full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205060s000lbl.pdf.
   Google Scholar
• Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017;26(2):251–259.
   PubMed Web of Science ®Google Scholar
• Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem. 2003;278(28):25468–25480.
   PubMed Web of Science ®Google Scholar
• Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Reviews Endocrinol. 2017;13(1):36–49.
   PubMed Web of Science ®Google Scholar
• Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5(9):542–553.
   PubMedGoogle Scholar
• Post SM, Duez H, Gervois PP, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21(11):1840–1845.
   PubMed Web of Science ®Google Scholar
• Bar-Tana J, Rose-Kahn G, Frenkel B, et al. Hypolipidemic effect of beta, beta’-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats. J Lipid Res. 1988;29(4):431–441.
   PubMed Web of Science ®Google Scholar
• Franceschini G, Poli A, Catapano AL, et al. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs. Atherosclerosis. 1981;40(3–4):245–255.
   PubMed Web of Science ®Google Scholar
• Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–733.
   PubMed Web of Science ®Google Scholar
• Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193–230.
   PubMed Web of Science ®Google Scholar
• Takizawa T, Murakami K, Yano W, et al. K-877, a highly potent and selective PPARα agonist, improves dyslipidemia and atherosclerosis in experimental animal models. 2012. (Abstract 787) EAS Congress abstract book. Available from:http://kenesforms.kenes.com/eas2012/abstracts/pdf/787.pdf
   Google Scholar
• Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol. 2013;12:82.
   PubMed Web of Science ®Google Scholar
• Dietz M, Mohr P, Kuhn B, et al. Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012;7(6):1101–1111.
   PubMed Web of Science ®Google Scholar
• Takizawa T, Inokuchi Y, Goto S, et al. The Mechanism of K-877, a Highly Potent and Selective Pparalpha Modulator, on Regulation of Synthesis, Secretion and Metabolism of Triglycerides and Cholesterol. Abstract 12867. Circulation 2013;128:A12867.
   Google Scholar
• Singh JP, Kauffman R, Bensch W, et al. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]prop yl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol Pharmacol. 2005;68(3):763–768.
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Locke KT, Miao B, et al. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther. 2008;327(3):716–726.
   PubMed Web of Science ®Google Scholar
• Rau O, Syha Y, Zettl H, et al. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma. Arch Pharm. 2008;341(3):191–195.
   Web of Science ®Google Scholar
• Davidson MH, Benes LB. The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016;27(6):570–578.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Shapiro MD. Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids. Endocr Pract. 2017;23(1):100–112.
   PubMed Web of Science ®Google Scholar
• Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb. 2015;22(8):754–772.
   PubMed Web of Science ®Google Scholar
• Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200–208.
   PubMed Web of Science ®Google Scholar
• Takei K, Han SI, Murayama Y, et al. The selective PPARalpha modulator K-877 efficiently activates the PPARalpha pathway and improves lipid metabolism in mice. J Diabetes Investig. 2017  Jan 13. doi: 10.1111/jdi.12621. [Epub ahead of print].
   Google Scholar
• Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36–43.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study. Eur Heart J. 2016;37(Abstract Supplement):1204.
   Google Scholar
• Schlein C, Talukdar S, Heine M, et al. FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab. 2016;23(3):441–453.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Senko Y, Hounslow N, et al. K877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus. European Heart Journal. 2015;36 (Abstract Supplement):1048.
   Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. Jama. 2007;297(12):1362–1373.
   PubMed Web of Science ®Google Scholar
• Millar JS, Duffy D, Gadi R, et al. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009;29(1):140–146.
   PubMed Web of Science ®Google Scholar
• Khera AV, Millar JS, Ruotolo G, et al. Potent peroxisome proliferator-activated receptor-alpha agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015;36(43):3020–3022.
   PubMed Web of Science ®Google Scholar
• Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis. 1998;137(Suppl):S19–23.
   PubMed Web of Science ®Google Scholar
• Arakawa R, Tamehiro N, Nishimaki-Mogami T, et al. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005;25(6):1193–1197.
   PubMed Web of Science ®Google Scholar
• Hossain MA, Tsujita M, Gonzalez FJ, et al. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol. 2008;51(3):258–266.
   PubMed Web of Science ®Google Scholar
• Ogata M, Tsujita M, Hossain MA, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009;205(2):413–419.
   PubMed Web of Science ®Google Scholar
• Shi Y, Li J, Kennedy LJ, et al. Discovery and preclinical evaluation of BMS-711939, an oxybenzylglycine based PPARalpha selective agonist. ACS Med Chem Lett. 2016;7(6):590–594.
   PubMed Web of Science ®Google Scholar
• Bernardes A, Souza PC, Muniz JR, et al. Molecular mechanism of peroxisome proliferator-activated receptor alpha activation by WY14643: a new mode of ligand recognition and receptor stabilization. J Mol Biol. 2013;425(16):2878–2893.
   PubMed Web of Science ®Google Scholar
• Huang D, Zhao Q, Liu H, et al. PPAR-alpha agonist WY-14643 inhibits LPS-induced inflammation in synovial fibroblasts via NF-kB pathway. J Mol Neurosci. 2016;59(4):544–553.
   PubMed Web of Science ®Google Scholar
• Urbatzka R, Galante-Oliveira S, Rocha E, et al. Effects of the PPARalpha agonist WY-14,643 on plasma lipids, enzymatic activities and mRNA expression of lipid metabolism genes in a marine flatfish, Scophthalmus maximus. Aqua Toxicol. 2015;164:155–162.
   PubMed Web of Science ®Google Scholar
• Pedraza N, Solanes G, Iglesias R, et al. Differential regulation of expression of genes encoding uncoupling proteins 2 and 3 in brown adipose tissue during lactation in mice. Biochem J. 2001;355(Pt 1):105–111.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun GJ, Ding J, et al. WY14643 combined with all-trans retinoic acid acts via p38 MAPK to induce “browning” of white adipocytes in mice. Genet Mol Res. 2015;14(2):6978–6984.
   PubMed Web of Science ®Google Scholar
• Janssen AW, Betzel B, Stoopen G, et al. The impact of PPARalpha activation on whole genome gene expression in human precision cut liver slices. BMC Genomics. 2015;16:760.
   PubMed Web of Science ®Google Scholar
• Kong L, Ren W, Li W, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids Health Dis. 2011;10:246.
   PubMed Web of Science ®Google Scholar
• Lebrun V, Molendi-Coste O, Lanthier N, et al. Impact of PPAR-alpha induction on glucose homoeostasis in alcohol-fed mice. Clin Sci. 2013;125(11):501–511.
   PubMed Web of Science ®Google Scholar
• Ip E, Farrell GC, Robertson G, et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003;38(1):123–132.
   PubMed Web of Science ®Google Scholar
• Ip E, Farrell G, Hall P, et al. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39(5):1286–1296.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. Jama. 2016;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.
   PubMedGoogle Scholar
• Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14(9):1481–1493.
   PubMed Web of Science ®Google Scholar
• Summary of the European public assessment report for Pravafenix. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001243/WC500106374.pdf.
   Google Scholar
• Troutt JS, Alborn WE, Cao G, et al. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res. 2010;51(2):345–351.
   PubMed Web of Science ®Google Scholar
• Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011;10:38.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Macchi C, et al. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2016;173:19–29.
   PubMed Web of Science ®Google Scholar
• Ferri N, Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine. 2016;54(3):588–601.
   PubMed Web of Science ®Google Scholar
• Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697.
   PubMed Web of Science ®Google Scholar
• Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780–1788.
   PubMed Web of Science ®Google Scholar
• Mombelli G, Banfi F, Falcioni S, et al. Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer. Int J Cardiol. 2009;133(3):412–414.
   PubMed Web of Science ®Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117(9):1444–1448.
   PubMed Web of Science ®Google Scholar
• Backes JM, Gibson CA, Ruisinger JF, et al. Fibrates: what have we learned in the past 40 years? Pharmacotherapy. 2007;27(3):412–424.
   PubMed Web of Science ®Google Scholar
• Magni P, Macchi C, Morlotti B, et al. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 2015;26(2):82–88.
   PubMed Web of Science ®Google Scholar
• Pierno S, Camerino GM, Cippone V, et al. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression. Br J Pharmacol. 2009;156(8):1206–1215.
   PubMed Web of Science ®Google Scholar
• Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest. 2015;45(7):745–754.
   PubMed Web of Science ®Google Scholar
• Belfort R, Berria R, Cornell J, et al. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010;95(2):829–836.
   PubMed Web of Science ®Google Scholar
• Read SH, Kerssens JJ, McAllister DA, et al. Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia. 2016;59(10):2106–2113.
   PubMed Web of Science ®Google Scholar
• Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: novel insight into factors, mechanisms, and therapeutics. J Cell Physiol. 2017;232(1):61–68.
   PubMed Web of Science ®Google Scholar
• Luo L, Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016;231(3):R77–R99.
   PubMed Web of Science ®Google Scholar
• Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab. 2014;20(3):396–407.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Rametta R, Meroni M, et al. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development–a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10(2):229–242.
   PubMed Web of Science ®Google Scholar
• Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs. 2014;23(10):1441–1448.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–59e5.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141(3):358–367.
   PubMed Web of Science ®Google Scholar
• Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635–1644.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–1133.
   PubMed Web of Science ®Google Scholar